Latest News and Press Releases

Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Vasculitis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's...

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. ...

NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and...

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic...

Transpire Bio Inc. has signed an exclusive license agreement with Suzhou Intragrand Pharma Co. for an investigational PDE4 inhibitor

Sanofi Licenses Nurix's STAT6 program

Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis...

600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study...

Data published in Obesity journal show enhanced weight loss effect of NT-0796 when combined with semaglutide in preclinical obesity modelObese state completely reversed with 30% weight loss and...

Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025. COO Valerie Ceva will...